The global hydroxychloroquine drug market is expected to grow at a significant CAGR during the forecast period (2021-2027).  Hydroxychloroquine is an immunosuppressive and anti-parasite therapy used to treat or prevent malaria; however, the drug is ineffective for chloroquine-resistant malaria. When other drugs fail or cannot be used to treat autoimmune diseases including systemic and discoid lupus erythematosus and rheumatoid arthritis (acute and severe), hydroxychloroquine is recommended by healthcare professionals. A variety of viruses can be treated using broad-spectrum hydroxychloroquine medicines. According to China's Ministry of Science and Technology, hydroxychloroquine is one of the medications that has shown promise in early clinical trials for inhibiting coronavirus.

The effectiveness of hydroxychloroquine drug in treating patients with COVID-19 disease has received attention, which in turn is boosting the growth of the market. Chloroquine has been shown to inhibit SARS-CoV-2 in vitro. The medicine was found to be highly effective in treating patients with infection. The COVID-19 disease drug hydroxychloroquine is expected to be a viable possible therapy. The US Food and Drug Administration (FDA) has approved hydroxychloroquine for use in treating COVID-19 disease as an emergency treatment. In March 2020, Novartis contributed up to 130 million doses of generic hydroxychloroquine to support the fight against the COVID-19 outbreak across the globe. 

Novartis started providing up to 130 million 200 mg tablets by the end of May 2020. The company is also looking into expanding production in order to improve supply, and it is committed to working with manufacturers all across the world to meet global demand. The Novartis Sandoz division only has a registration for hydroxychloroquine in the US and is working with the FDA and the European Medicines Agency to obtain the necessary regulatory approvals. Since the emergence of COVID-19, Zydus Cadila has increased its capacity for manufacturing hydroxychloroquine by roughly tenfold. Zydus and IPCA Labs are the two largest manufacturers of hydroxychloroquine in India, accounting for 70% of global supply. Previously, the company produced 2-4 tonnes API per month for both local and export markets, however,  in April 2020, it met a new domestic target of 20 tonnes API, or 10 crore tablets. The company further stated that drug manufacturing in Sikkim is operating at full capacity. Other locations have 60-70% manufacturing capacity, which increased every day. Plants for Zydus can be found in Baddi, Ahmedabad, Daman, Sikkim, and Goa, as well as API plants in Vadodara and Ankleshwar. Ahmedabad, Sikkim, and Baddi are among the places where hydroxychloroquine tablets are made.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Application 

o By Dosage Type

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Cipla Ltd., Sanofi S.A., Ipca Laboratories Ltd., Novartis International AG, and Teva Pharmaceutical Industries Ltd. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Hydroxychloroquine Drug Market Report by Segment

By Application 

• COVID-19
• Malaria
• Rheumatoid Arthritis
• Others (Lupus Erythematosus)

By Dosage Type

• 100 mg
• 200 mg
• 400 mg
• 600 mg
• 800 mg

Global Hydroxychloroquine Drug Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa